Ethnic Bridging in Phase 1 Clinical Trials:

A Strategy for Enhancing Asset Value and Accelerating Global Drug Development


WCCT Global will be participating in an Xtalks webinar on Tuesday, February 5th. Xtalks provides viewers with a window into the latest developments in the medical industry, giving members of the community an opportunity to hear directly from the experts who are leading the way in the field.


Mel Affrime, PharmD, President and Chief Scientific Officer of WCCT, will be presenting:

Ethnic Bridging in Phase 1 Clinical Trials: A Strategy for Enhancing Asset Value and Accelerating Global Drug Development

The possibility that ethnic differences exist in different populations with regards to drug metabolism and distribution has been documented for many years. These observed differences may be manifest in alterations in safety, efficacy and/or labeled dosages, or in terms of adverse event profiles in patients residing in different geographic regions. This created the perceived necessity to fully and separately develop new medicines for each geographic market.

This development practice evolved into a trend such that drug development was initiated in the USA or Europe, and development in other geographic regions followed in such countries as Japan, South Korea and Taiwan. Development in Canada, Australia, New Zealand, South Africa and South America generally kept pace with development in the USA and Europe. Consequently, throughout the 1980s and early 1990s there was an acknowledged 7 to 10 year ‘drug approval lag’ in Japan, South Korea and Taiwan. Thus, these populations suffered delayed access to new therapies even though safety and efficacy had already been established in other regions of the world. Consequently, it was difficult to explain to the patients residing in these regions why they had to wait so many years beyond the rest of the world to get access to these medications. The urgent need to rationalize and harmonize regulations was understood by regulators worldwide, as well as the global pharmaceutical industry. As a result, ICH E5 – Ethnic Factors in the Acceptability of Foreign Clinical Data (5 Feb 1998) was published and the concept of global clinical development was widely and rapidly adopted.

Quicker development time means increased valuation of your asset due to the ability to achieve commercial milestones earlier than through regional-specific development program management. Join this webinar to hear about specific case studies and strategies on how to include ethnic bridging in your early clinical development plans to hasten regulatory acceptance of data worldwide.


Join Xtalks and register for the webinar to access cutting-edge industry information tailored to your interests.


You can view the event details below:

Date:               Tuesday, February 05, 2019

Time:               2pm EST (11am PST)

Duration:         60 minutes